PEZATRESGENE LEUCEL
UNII E4Y8KU8Q77

Substance Identification & Data

This profile provides standardized clinical and technical data for Pezatresgene Leucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) E4Y8KU8Q77.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

E4Y8KU8Q77

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PEZATRESGENE LEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C221001

National Cancer Institute reference terminology for clinical and research data.

INN ID

13440

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Pezatresgene Leucel

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pezatresgene Leucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Pezatresgene Leucel

Common Names & Synonyms

allogeneic T lymphocytes derived from peripheral blood mononuclear cells (PBMCs) of a haploidentical hematopoietic cell transplantation (HCT) donor that is negative for the HA-1 genotype and/or negative for HLA A*02, engineered by transposon/transposase-mediated gene delivery to express a T cell receptor (TCR) that is specific for a 9-amino acid peptide (VLHDDLLEA) termed HA-1 derived from the Rho GTPaseactivating protein 45 (ARHGAP45) and presented on HLAA* 02:01. The TCR comprises α and β subunits separated by a P2A self-cleaving peptide. The transgene also encodes a codonoptimised CD8 co-receptor consisting of α and β chains separated by a P2A self-cleaving peptide, with the CD8 co-receptor separated from the TCR by an additional P2A self-cleaving peptide. Each P2A sequence is preceded by a furin cleavage site. A 16 amino acid epitope encoding a portion of human CD34 is incorporated into the N-terminus of the CD8α chain. The transgene is under the control of a murine stem cell virus (MSCV) promoter, a Woodchuck hepatitis virus post-transcriptional response element and a simian virus 40 (SV40) polyadenylation (polyA) signal. The transposase (Armyworm transposase) is introduced in form of an mRNA that comprises an anti-reverse cap analogue, a Xenopus globin 5' untranslated region (UTR), a Kozak sequence, the transposase open reading frame, and a Xenopus globin 3' UTR. The transgene is introduced via a nanoplasmid DNA vector and contains inverted terminal repeats (ITRs). The leukapheresis material is electroporated with mRNA transposase as well as the nanoplasmid transposon followed by activation with CD2, CD3 and CD28 agonists. The cells are then grown in serum free media supplemented with interleukin 2 (IL-2), interleukin 7 (IL-7) and interleukin 15 (IL-15). The T lymphocytes (≥95%) are positive for the transgene (≥80% TCR+) and release interferon- gamma (IFN-γ) in response to co-culture with THP-1 cells that express the HA-1 target peptide

pezatresgene leucel [INN]

External Clinical & Regulatory Resources

Previous UNIIE4Y5YL4FTG

Next UNIIE4YB2F3H6Y